📄️ Bridge round deck
Company update and bridge-round overview presented to shareholders (July 2026). Navigate with the on-screen arrows or your keyboard. For a full-screen view, open the deck in a new tab.
📄️ Bridge Thesis
The proposition
📄️ Path to €1M ARR
The bridge round funds the acceleration from our Budget trajectory (conservative, organic) to our Model trajectory (€1M ARR, the level that opens Series A). Both scenarios are derived from internal financial planning. The gap between them is what the bridge capital activates.
📄️ Use of Funds
Allocation of the €2M bridge (€750K convertible + €600K loans + a partial grant award; fuller grant awards are non-dilutive upside on top). Every euro is tied to a measurable outcome that contributes to the path from €401K to €1M ARR, the milestone that opens the Series A.
📄️ Value Creation Since Seed
In the 21 months since closing the seed round (September 2024), Legit.Health has built the platform required for accelerated growth: a commercial team, new tier-1 customer logos, additional regulatory certifications, scientific output, captured grants, and operational maturity. Top-line revenue undershot the optimistic 2024 budget, but every foundational asset that drives the next phase is now in place.